NCT00093964 2019-04-16
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
EMD Serono
Phase 2 Completed
Clinical Trials
11 trialsNCT01782976 2018-01-19
Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00112866 2017-06-14
Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00813943 2017-01-30
CORE
EMD Serono
Phase 2 Completed
NCT00085254 2016-02-25
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01517776 2015-07-21
HGG-CilMetro
Martin-Luther-Universität Halle-Wittenberg
Phase 2 Terminated
NCT01122888 2015-04-28
Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00979862 2015-04-15
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00006093 2013-06-24
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01044225 2012-03-22
Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma
Universitair Ziekenhuis Brussel
Phase 2 Terminated
NCT01124240 2011-07-26
ExCentric
Northern Sydney and Central Coast Area Health Service
Phase 2 Unknown